Analytical Data
-
基因名
DEFB129
- Application
-
别名
Beta-defensin 29 Defensin, beta 129
-
种属
Human
-
表达系统
Yeast
-
标签
C- His-Myc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9H1M3
-
表达区间
20-183aa
-
分子量
21.8 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Defensin beta 129 (DEFB129) is a member of the beta-defensin family, which plays a crucial role in the innate immune response. It is primarily expressed in human epithelial tissues, including the skin, respiratory tract, and gastrointestinal system. The unique antimicrobial properties of DEFB129 make it a subject of interest in research aimed at understanding its role in host defense against pathogens. Studies have shown that DEFB129 exhibits antibacterial, antifungal, and antiviral activities, indicating its potential as a therapeutic agent in combating infections. Additionally, its involvement in modulating inflammation and promoting wound healing highlights its relevance in various clinical conditions. The recombinant expression of DEFB129 has enabled researchers to produce this protein in sufficient quantities for detailed analysis of its structure-function relationship and mechanism of action. Investigating the potential applications of DEFB129 in drug development, particularly in the context of increasing antibiotic resistance, is of significant importance. Overall, the study of DEFB129 recombinant protein offers valuable insights into the development of novel therapeutic strategies to enhance immune responses and fight infections.
